small molecule neoantigen immuno-oncology company
NeoPhore has raised €10M across 2 funding rounds from 6 investors, most recently a Series B round in Jan 2023. Based in Cambridge, UK; active in Healthtech. Data as of 7 Aug 2026.
Timing: overdue vs cohort gap · momentum up. Funding-only estimates, not predictions and not investment advice — see signals.
| Date |
|---|
| Stage |
|---|
| Amount |
|---|
| Investors |
|---|
| 2023-01-19 | Series B | €6.8M | 2Invest,3B Future Health Fund,Astellas Venture Management,Claris Ventures,CRT Pioneer Fund | View deal → |
| 2017-11-16 | Other | €3.3M | Sixth Element Capital LLP (6EC) | View deal → |
